Kurs
-1,48%
Likviditet
30,0 MSEK
Kalender
| Est. tid* | ||
| 2027-01-28 | 08:00 | Bokslutskommuniké 2026 |
| 2026-10-22 | 08:00 | Kvartalsrapport 2026-Q3 |
| 2026-07-16 | 08:00 | Kvartalsrapport 2026-Q2 |
| 2026-05-06 | - | X-dag ordinarie utdelning VITR 1.10 SEK |
| 2026-05-05 | - | Årsstämma |
| 2026-04-23 | - | Kvartalsrapport 2026-Q1 |
| 2026-02-03 | - | Bokslutskommuniké 2025 |
| 2025-10-23 | - | Kvartalsrapport 2025-Q3 |
| 2025-07-17 | - | Kvartalsrapport 2025-Q2 |
| 2025-04-30 | - | X-dag ordinarie utdelning VITR 1.10 SEK |
| 2025-04-29 | - | Årsstämma |
| 2025-04-24 | - | Kvartalsrapport 2025-Q1 |
| 2025-01-30 | - | Bokslutskommuniké 2024 |
| 2024-10-24 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-17 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-26 | - | X-dag ordinarie utdelning VITR 1.00 SEK |
| 2024-04-25 | - | Årsstämma |
| 2024-04-18 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-02 | - | Bokslutskommuniké 2023 |
| 2023-10-27 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-14 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-28 | - | X-dag ordinarie utdelning VITR 0.85 SEK |
| 2023-04-27 | - | Årsstämma |
| 2023-04-21 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-02 | - | Bokslutskommuniké 2022 |
| 2022-10-27 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-15 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-28 | - | X-dag ordinarie utdelning VITR 0.80 SEK |
| 2022-04-27 | - | Årsstämma |
| 2022-04-22 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2021-10-29 | - | Kvartalsrapport 2021-Q3 |
| 2021-10-20 | - | Extra Bolagsstämma 2021 |
| 2021-07-15 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-29 | - | X-dag ordinarie utdelning VITR 0.80 SEK |
| 2021-04-28 | - | Årsstämma |
| 2021-04-22 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-10 | - | Bokslutskommuniké 2020 |
| 2020-11-06 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-13 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-16 | - | X-dag ordinarie utdelning VITR 0.00 SEK |
| 2020-06-15 | - | Årsstämma |
| 2020-04-23 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-06 | - | Bokslutskommuniké 2019 |
| 2019-11-06 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-12 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-03 | - | X-dag ordinarie utdelning VITR 0.85 SEK |
| 2019-05-02 | - | Årsstämma |
| 2019-04-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-08 | - | Bokslutskommuniké 2018 |
| 2018-11-06 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-13 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-17 | - | Split VITR 1:5 |
| 2018-04-27 | - | X-dag ordinarie utdelning VITR 3.70 SEK |
| 2018-04-26 | - | Årsstämma |
| 2018-04-24 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-08 | - | Bokslutskommuniké 2017 |
| 2017-11-02 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-14 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-28 | - | X-dag ordinarie utdelning VITR 2.60 SEK |
| 2017-04-27 | - | Årsstämma |
| 2017-04-25 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-09 | - | Bokslutskommuniké 2016 |
| 2016-11-03 | - | Kvartalsrapport 2016-Q3 |
| 2016-09-20 | - | Kapitalmarknadsdag 2016 |
| 2016-07-15 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-29 | - | X-dag ordinarie utdelning VITR 2.40 SEK |
| 2016-04-28 | - | Årsstämma |
| 2016-04-26 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-05 | - | Bokslutskommuniké 2015 |
| 2015-11-05 | - | Kvartalsrapport 2015-Q3 |
| 2015-07-14 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-06 | - | X-dag ordinarie utdelning VITR 1.50 SEK |
| 2015-05-05 | - | Årsstämma |
| 2015-04-28 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-06 | - | Bokslutskommuniké 2014 |
| 2014-11-06 | - | Analytiker möte 2014 |
| 2014-11-06 | - | Kapitalmarknadsdag 2014 |
| 2014-11-06 | - | Kvartalsrapport 2014-Q3 |
| 2014-07-11 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-06 | - | X-dag ordinarie utdelning VITR 1.00 SEK |
| 2014-05-05 | - | Årsstämma |
| 2014-04-23 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-06 | - | Bokslutskommuniké 2013 |
| 2013-11-11 | - | Kapitalmarknadsdag 2013 |
| 2013-11-07 | - | Analytiker möte 2013 |
| 2013-11-07 | - | Kvartalsrapport 2013-Q3 |
| 2013-07-12 | - | Kvartalsrapport 2013-Q2 |
| 2013-04-30 | - | X-dag ordinarie utdelning VITR 0.60 SEK |
| 2013-04-29 | - | Årsstämma |
| 2013-04-19 | - | Kvartalsrapport 2013-Q1 |
| 2013-03-13 | - | 15-7 2013 |
| 2013-02-07 | - | Bokslutskommuniké 2012 |
| 2012-11-01 | - | Analytiker möte 2012 |
| 2012-11-01 | - | Kvartalsrapport 2012-Q3 |
| 2012-09-24 | - | Extra Bolagsstämma 2012 |
| 2012-07-13 | - | Kvartalsrapport 2012-Q2 |
| 2012-04-20 | - | X-dag ordinarie utdelning VITR 0.60 SEK |
| 2012-04-19 | - | Årsstämma |
| 2012-04-19 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-07 | - | Bokslutskommuniké 2011 |
| 2011-10-27 | - | Kvartalsrapport 2011-Q3 |
| 2011-07-14 | - | Kvartalsrapport 2011-Q2 |
| 2011-04-28 | - | X-dag ordinarie utdelning VITR 0.60 SEK |
| 2011-04-27 | - | Årsstämma |
| 2011-04-27 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-09 | - | Bokslutskommuniké 2010 |
| 2010-11-02 | - | Kvartalsrapport 2010-Q3 |
| 2010-07-15 | - | Kvartalsrapport 2010-Q2 |
| 2010-04-27 | - | X-dag ordinarie utdelning VITR 0.50 SEK |
| 2010-04-27 | - | Kvartalsrapport 2010-Q1 |
| 2010-04-26 | - | Årsstämma |
| 2010-02-05 | - | Bokslutskommuniké 2009 |
| 2009-11-03 | - | Kvartalsrapport 2009-Q3 |
| 2009-07-15 | - | Kvartalsrapport 2009-Q2 |
| 2009-04-28 | - | X-dag ordinarie utdelning VITR 0.40 SEK |
| 2009-04-27 | - | Årsstämma |
| 2009-04-27 | - | Kvartalsrapport 2009-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Vitrolife AB (publ) today announces that CEO Bronwyn Brophy O'Connor has decided to leave the company to assume a CEO role in a different area of the medtech industry. Vitrolife Group's Board has received Bronwyn's resignation and will immediately begin the recruitment process for a new CEO.
Bronwyn will remain in her role during her notice period for up to 12 months to ensure a smooth transition to her successor. The Board, supported by international recruitment specialists, will immediately initiate the search for Bronwyn’s successor who can strategically guide and advance the company on its path to continued innovation and long-term growth. Both internal and external candidates will be considered as part of this process.
“On behalf of Vitrolife Group’s Board, I want to thank Bronwyn for her dedication and significant contributions during her three years as CEO. We have seen Bronwyn develop as a leader, and we are proud to have been part of her journey. As she takes the next step toward an exciting new role, we recognize this as a great opportunity for her and respect her decision. We wish Bronwyn every success in her future endeavors,” says Jón Sigurdsson, Chairman of the Board.
“Leading the Vitrolife Group is an honor and a privilege. I will leave with mixed feelings, and will miss our fantastic colleagues around the world, and the vision we share to enable people to fulfill the dream of having a healthy baby. Vitrolife Group is truly on a path to becoming the leading global partner in reproductive health. In the next phase of my career, I will join a renowned company, in a different area of the medtech industry at an exciting time in its history”, says Bronwyn Brophy O'Connor.
Gothenburg, 22 May 2026
VITROLIFE AB (publ)
This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 22-05-2026 12:00 CET.
Contact:
Jón Sigurdsson, Chairman of the Board
email: jon@emblamedical.com
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,150 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.
Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com.